Various monoclonal antibodies (mAbs) and anticalines targeting c‐Met or its ligand (HGF), for example, DN30, rilotumumab, onartuzumab, and PRS‐100, have been recently tested in both preclinical and clinical trials, with encouraging results for the management of cancer.54, 55, 56. This evidence concerns the gene HGF and cancer.